[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-628941-105":59,"doc-detail-628941-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","nano-based-drug-delivery-systems-for-the-treatment-of-non-infectious-uveitis-review","Nano-based Drug Delivery Systems for the Treatment of Non-infectious Uveitis - Review","","Uveitis is a leading cause of global visual impairment, and non-infectious uveitis (NIU) is commonly treated with corticosteroids, immunosuppressants, and biologics. However, ocular anatomical barriers and drug-related adverse effects limit treatment efficacy. This review analyzes how nano-based drug delivery systems can improve bioavailability and therapeutic outcomes by enabling targeted delivery, sustained release, and reduced side effects. Liposomes, dendrimers, hydrogels, nanoparticles, nanomicelles, nanosuspensions, and nanoemulsions are highlighted as promising intraocular approaches.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nano-based-drug-delivery-systems-for-the-treatment-of-non-infectious-uveitis-review/628941/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nano-based-drug-delivery-systems-for-the-treatment-of-non-infectious-uveitis-review/628941.png","ImageObject",300,407,{"name":92,"@type":93},"Bulrr","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-10-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What challenges limit current treatments for non-infectious uveitis (NIU)?","Question",{"text":113,"@type":114},"Ocular anatomical barriers and adverse drug side effects hinder effective delivery and outcomes. Systemic therapy is limited by side effects and insufficient drug accumulation at the disease site.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do nano-based drug delivery systems (DDS) aim to improve NIU therapy?",{"text":118,"@type":114},"Nano-based DDS are designed for targeted delivery, enhanced bioavailability, sustained release, reduced side effects, and improved therapeutic efficacy despite ocular barriers.",{"name":120,"@type":111,"acceptedAnswer":121},"Which types of nano-based intraocular DDS are reviewed for NIU treatment?",{"text":122,"@type":114},"The review highlights several categories, including liposomes, dendrimers, hydrogels, nanoparticles, nanomicelles, nanosuspensions, and nanoemulsions.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},628941,1792694599,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Advances in Ophthalmology Practice and Research 5 (2025) 124–134  \nContents lists available at ScienceDirect  \nAdvances in Ophthalmology Practice and Research  \njournal [homepage:](homepage: www.journals.elsevier.com/advances-in-ophthalmology-practice-and-research)[ www.journals.elsevier.com/advances-in-ophthalmology-practice-and-research](homepage: www.journals.elsevier.com/advances-in-ophthalmology-practice-and-research)  \nReview  \nNano-based drug delivery systems for the treatment of non-infectious uveitis Xingdi Wu a, b, 1, Mengyuan Hu a, b, 1, Yilu Cai c, Fan Jia d, e, Yang Ye a, b, Naiji Yu a, b, Min Chen a, b, **, Kaijun Wang a, b, *  \na Department of Ophthalmology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China b Zhejiang Provincial Key Lab of Ophthalmology, Hangzhou, China  \nc Zhejiang University School of Medicine, Hangzhou, China  \nd MOE Key Laboratory of Macromolecule Synthesis and Functionalization of Ministry of Education, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, China  \ne Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China  \n| A R T I C L E I N F O |  | A B S T R A C T |\n| --- | --- | --- |\n| Keywords:\u003Cbr>Non-infectious uveitis Ocular barriers Drug delivery systems Nanocarriers Pharmacotherapy |  | Background: Uveitis is one of the most prevalent causes of global visual impairment. The current approaches to treating non-infectious uveitis (NIU) involve the utilization of corticosteroids, immunosuppressant and biologics agents. Nevertheless, the intricate ocular anatomy barriers and adverse side effects of the drugs pose significant obstacles to effective treatment outcomes.\u003Cbr>Main text: To improve drug bioavailability and therapeutic outcomes for NIU while minimize side effects, researchers are committed to developing novel nano-based drug delivery systems (DDS), which have the capacity to achieve targeted delivery, increase bioavailability, achieve sustained release, reduce side effects and improve therapeutic effects. Thus, DDS based on nanotechnology, including liposome, dendrimer, hydrogels, nanoparticles, nanomicelles, nanosuspensions and nanoemulsions have emerged as promising alternatives to conventional ocular delivery methods for the management of NIU.\u003Cbr>Conclusions: In this review, we summarize the current therapeutic challenges faced by NIU and describe various nano-based intraocular DDS involved in the treatment of NIU. It is concluded that nano-based DDS is an appealing approach to addressing the unmet needs for the treatment of NIU. |\n\n1. Introduction  \nUveitis, marked by intraocular inflammation affecting the iris, ciliary body, and choroid, manifests with symptoms such as pain, redness, photophobia, and shed tears.1 The estimated incidence of uveitis ranges from 17 to 52 cases per 100000 population. It is believed to account for 5%–20% of total blindness in the developed world and 25% in the developing world. The increased social morbidity of uveitis is most common in working-age adults (aged 20–59 years).2,3 Uveitis can be categorized based on the anatomical site of inflammation as anterior, intermediate, or posterior, and can also manifest as panuveitis, involving inflammation across all 3 components of the uvea.4 Additionally, uveitisis also classified by its etiology, such as infectious causes, non-infectious origins, and masquerade syndromes.5 This review specifically focuses on  \nnon-infectious uveitis (NIU). Idiopathic cases, accounting for 35%–57% of uveitis cases, cannot be classified within specific ocular syndromes because of the absence of associated systemic diseases.6 The etiology of NIU remains incompletely understood, which requires further exploration of its inflammatory mechanisms to alleviate ocular inflammation and improve treatment effectiveness. Despite the","cbCaidujpvbGELGq","https://ap.wps.com/l/cbCaidujpvbGELGq","pdf",1077492,"English","# 1. Introduction\n## Uveitis background and classification\n## Current clinical treatment and need for safer strategies\n# Medication treatments in NIU\n## Systemic therapy vs topical administration\n# Nano-based drug delivery systems (DDS)\n## Rationale and expected advantages","[{\"question\":\"What challenges limit current treatments for non-infectious uveitis (NIU)?\",\"answer\":\"Ocular anatomical barriers and adverse drug side effects hinder effective delivery and outcomes. Systemic therapy is limited by side effects and insufficient drug accumulation at the disease site.\"},{\"question\":\"How do nano-based drug delivery systems (DDS) aim to improve NIU therapy?\",\"answer\":\"Nano-based DDS are designed for targeted delivery, enhanced bioavailability, sustained release, reduced side effects, and improved therapeutic efficacy despite ocular barriers.\"},{\"question\":\"Which types of nano-based intraocular DDS are reviewed for NIU treatment?\",\"answer\":\"The review highlights several categories, including liposomes, dendrimers, hydrogels, nanoparticles, nanomicelles, nanosuspensions, and nanoemulsions.\"}]","Nano-based Drug Delivery Systems for the Treatment of Non-infectious Uveitis - Review | PDF",1792620007,28]